11:41 AM
 | 
Jan 09, 2019
 |  BC Extra  |  Company News

Senior FDA official to head government affairs at CRISPR Therapeutics

John Martin, principal associate commissioner for legislative affairs at FDA, is leaving the agency and joining CRISPR Therapeutics AG (NASDAQ:CRSP) as head of government affairs.

Martin, who joined FDA in 2017, led the agency's negotiation with Congress over reauthorization of user fees, and supported FDA’s writing of draft legislation that seeks to revamp regulation of diagnostics, including laboratory developed tests (see “Debating Diagnostics”).

In a memo to agency staff, FDA Commissioner Scott Gottlieb highlighted Martin’s work on legislation to address the opioid abuse epidemic. “Perhaps the most impactful effort John oversaw for the agency was work done to support the passage of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, which gave the agency watershed new authorities to build on the important work we’re undertaking to change the trajectory of the opioid crisis.”

FDA has identified and will soon announce a permanent replacement for Martin, Gottlieb wrote. Maren McBride, FDA’s legislative director for appropriations, will fill Martin’s position on an interim basis.

CRISPR climbed $2.72 to $36.73 on Wednesday.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD